July 20, 2022
UC San Diego researchers provide first insights into the fundamental cellular pathologies that drive interstitial lung disease in patients post-COVID.
June 23, 2022
A $10 million grant over four years will support further examination of a national study looking at COVID-19 vaccination safety during pregnancy and immune response pre-and post-delivery for both mom and baby.
June 21, 2022
COVID-19 rebound following Paxlovid treatment likely due to insufficient drug exposure, UC San Diego researchers find after showing rebound patient did not show drug resistance or impaired immunity.
June 17, 2022
UC San Diego researchers report significant decrease in national cases of Kawasaki disease during COVID-19 pandemic; findings hint at origins of disease.
June 15, 2022
A UC San Diego study describes the short- and long-term neurological symptoms of SARS-CoV-2 infection, and identifies a new group of COVID-19 long-haulers with advanced motor and cognitive symptoms.
May 16, 2022
COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.
April 6, 2022
UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
April 4, 2022
Charitable giving increased in counties that experienced COVID-19-related deaths, reveals a new study from the University of California San Diego’s Rady School of Management published in Nature’s Scientific Reports.
March 21, 2022
UC San Diego Health is now administering Evusheld to eligible, immunocompromised patients to protect against the COVID-19 virus.
March 17, 2022
UC San Diego study shows neuroendocrine cells in the lungs drive a developmental lung disease, and a similar brain-lung interaction may contribute to COVID-19 symptoms. The findings suggest neuropeptides may be a promising therapeutic target for conditions with excess lung fluid.